164 related articles for article (PubMed ID: 29783099)
1. Leveraging the cruzain S3 subsite to increase affinity for reversible covalent inhibitors.
Cianni L; Sartori G; Rosini F; De Vita D; Pires G; Lopes BR; Leitão A; Burtoloso ACB; Montanari CA
Bioorg Chem; 2018 Sep; 79():285-292. PubMed ID: 29783099
[TBL] [Abstract][Full Text] [Related]
2. Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles.
Dos Santos AM; Cianni L; De Vita D; Rosini F; Leitão A; Laughton CA; Lameira J; Montanari CA
Phys Chem Chem Phys; 2018 Sep; 20(37):24317-24328. PubMed ID: 30211406
[TBL] [Abstract][Full Text] [Related]
3. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
4. Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.
Mott BT; Ferreira RS; Simeonov A; Jadhav A; Ang KK; Leister W; Shen M; Silveira JT; Doyle PS; Arkin MR; McKerrow JH; Inglese J; Austin CP; Thomas CJ; Shoichet BK; Maloney DJ
J Med Chem; 2010 Jan; 53(1):52-60. PubMed ID: 19908842
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cysteine proteases by a natural biflavone: behavioral evaluation of fukugetin as papain and cruzain inhibitor.
Assis DM; Gontijo VS; de Oliveira Pereira I; Santos JA; Camps I; Nagem TJ; Ellena J; Izidoro MA; dos Santos Tersariol IL; de Barros NM; Doriguetto AC; dos Santos MH; Juliano MA
J Enzyme Inhib Med Chem; 2013 Aug; 28(4):661-70. PubMed ID: 22468751
[TBL] [Abstract][Full Text] [Related]
6. Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain.
Huang L; Brinen LS; Ellman JA
Bioorg Med Chem; 2003 Jan; 11(1):21-9. PubMed ID: 12467703
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new class of nonpeptidic inhibitors of cruzain.
Brak K; Doyle PS; McKerrow JH; Ellman JA
J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536
[TBL] [Abstract][Full Text] [Related]
8. Novel cruzain inhibitors for the treatment of Chagas' disease.
Rogers KE; Keränen H; Durrant JD; Ratnam J; Doak A; Arkin MR; McCammon JA
Chem Biol Drug Des; 2012 Sep; 80(3):398-405. PubMed ID: 22613098
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the Cruzain Cysteine Protease Reversible and Irreversible Covalent Inhibition Mechanism.
Silva JRA; Cianni L; Araujo D; Batista PHJ; de Vita D; Rosini F; Leitão A; Lameira J; Montanari CA
J Chem Inf Model; 2020 Mar; 60(3):1666-1677. PubMed ID: 32126170
[TBL] [Abstract][Full Text] [Related]
10. First quantum mechanics/molecular mechanics studies of the inhibition mechanism of cruzain by peptidyl halomethyl ketones.
Arafet K; Ferrer S; Moliner V
Biochemistry; 2015 Jun; 54(21):3381-91. PubMed ID: 25965914
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Scheidt KA; Roush WR; McKerrow JH; Selzer PM; Hansell E; Rosenthal PJ
Bioorg Med Chem; 1998 Dec; 6(12):2477-94. PubMed ID: 9925304
[TBL] [Abstract][Full Text] [Related]
12. Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.
Neitz RJ; Bryant C; Chen S; Gut J; Hugo Caselli E; Ponce S; Chowdhury S; Xu H; Arkin MR; Ellman JA; Renslo AR
Bioorg Med Chem Lett; 2015 Nov; 25(21):4834-4837. PubMed ID: 26144347
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
Espíndola JW; Cardoso MV; Filho GB; Oliveira E Silva DA; Moreira DR; Bastos TM; Simone CA; Soares MB; Villela FS; Ferreira RS; Castro MC; Pereira VR; Murta SM; Sales Junior PA; Romanha AJ; Leite AC
Eur J Med Chem; 2015 Aug; 101():818-35. PubMed ID: 26231082
[TBL] [Abstract][Full Text] [Related]
14. Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases.
Silva LR; Guimarães AS; do Nascimento J; do Santos Nascimento IJ; da Silva EB; McKerrow JH; Cardoso SH; da Silva-Júnior EF
Bioorg Med Chem; 2021 Jul; 41():116213. PubMed ID: 33992862
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of Leishmania mexicana cysteine protease B in complex with a high-affinity azadipeptide nitrile inhibitor.
Ribeiro JFR; Cianni L; Li C; Warwick TG; de Vita D; Rosini F; Dos Reis Rocho F; Martins FCP; Kenny PW; Lameira J; Leitão A; Emsley J; Montanari CA
Bioorg Med Chem; 2020 Nov; 28(22):115743. PubMed ID: 33038787
[TBL] [Abstract][Full Text] [Related]
16. Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain.
Roush WR; Cheng J; Knapp-Reed B; Alvarez-Hernandez A; McKerrow JH; Hansell E; Engel JC
Bioorg Med Chem Lett; 2001 Oct; 11(20):2759-62. PubMed ID: 11591518
[TBL] [Abstract][Full Text] [Related]
17. Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and
Boudreau PD; Miller BW; McCall LI; Almaliti J; Reher R; Hirata K; Le T; Siqueira-Neto JL; Hook V; Gerwick WH
J Med Chem; 2019 Oct; 62(20):9026-9044. PubMed ID: 31539239
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biochemical evaluation and molecular modeling studies of nonpeptidic nitrile-based fluorinated compounds.
Fonseca Lameiro RD; Shamim A; Rosini F; Cendron R; Jatai Batista PH; Montanari CA
Future Med Chem; 2021 Jan; 13(1):25-43. PubMed ID: 33289603
[No Abstract] [Full Text] [Related]
19. Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors.
Avelar LA; Camilo CD; de Albuquerque S; Fernandes WB; Gonçalez C; Kenny PW; Leitão A; McKerrow JH; Montanari CA; Orozco EV; Ribeiro JF; Rocha JR; Rosini F; Saidel ME
PLoS Negl Trop Dis; 2015; 9(7):e0003916. PubMed ID: 26173110
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
de Souza ML; de Oliveira Rezende Junior C; Ferreira RS; Espinoza Chávez RM; Ferreira LLG; Slafer BW; Magalhães LG; Krogh R; Oliva G; Cruz FC; Dias LC; Andricopulo AD
J Chem Inf Model; 2020 Feb; 60(2):1028-1041. PubMed ID: 31765144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
